[Cultivation and Standardized Technology Research on A New Astragalus Variety of Longqi 4].

中药材 Pub Date : 2016-09-01

Fu-sheng Wang, Hu-shan Shang, Xiao-chun Pan

{"title":"[Cultivation and Standardized Technology Research on A New Astragalus Variety of Longqi 4].","authors":"Fu-sheng Wang, Hu-shan Shang, Xiao-chun Pan","doi":"","DOIUrl":null,"url":null,"abstract":"Objective: To breed a new Astragalus variety and to study its standard cultivation techniques, which are high yield, good quality, disease resistance, anti-reverse with intrinsic quality in line with the standard of the Pharmacopoeia of the People’ s Republic of China.Methods: By using the method of single plant selection,15 excellent individual plants were selected in 2003→seed period tested in 2004→strains identification tested from 2005 to 2007 → new strains comparison tested for HQZX04-04-01 in medicine period from2008 to 2010→regional tested and production demonstration for HQZX04-04-01 from 2011 to 2014→Longqi 4 was named by Crop Variety Approval Committee of Gansu Province in April,2015.Results: A new Astragalus variety of Longqi 4( the original code HQZX04-04-01) was bred. By 3 n tests in different ecological zones, the average yield of fresh Astragalus root was 708. 9 kg /666. 7 m2,and was31. 1% increased compared with the control variety; special / first class rate was 21. 5%,30. 6%,in which were 4. 8,5. 3 percentage points higher than that of the control variety, respectively; root rot disease incidence and disease index were 25. 7%,13. 5%,in which were 2. 75,2. 17 percentage points reduced compared with control variety; intrinsic quality were as follows, the total ash was 4. 5%,the extract was 41. 0%,the content of calycosin was 0. 10%,and the content of astragaloside was 0. 076%,respectively,which superior than the 2010 edition of the standard of the Pharmacopoeia of the People’ s Republic of China.Conclusion: A new Astragalus variety of Longqi 4 is high-yield, good-quality, disease-resistant, anti-inverse and its intrinsic quality in lines with the standard of the Pharmacopoeia of the People’s Republic of China. Longqi 4 is suitable for application at an altitude of 1 900 ~ 2 400 m, the annual average temperature of 5 ~ 8 ℃,semi-arid and cold damp ecological area of annual precipitation of 450 ~ 550 mm.","PeriodicalId":15312,"journal":{"name":"中药材","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2016-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中药材","FirstCategoryId":"3","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To breed a new Astragalus variety and to study its standard cultivation techniques, which are high yield, good quality, disease resistance, anti-reverse with intrinsic quality in line with the standard of the Pharmacopoeia of the People’ s Republic of China.

Methods: By using the method of single plant selection,15 excellent individual plants were selected in 2003→seed period tested in 2004→strains identification tested from 2005 to 2007 → new strains comparison tested for HQZX04-04-01 in medicine period from2008 to 2010→regional tested and production demonstration for HQZX04-04-01 from 2011 to 2014→Longqi 4 was named by Crop Variety Approval Committee of Gansu Province in April,2015.

Results: A new Astragalus variety of Longqi 4( the original code HQZX04-04-01) was bred. By 3 n tests in different ecological zones, the average yield of fresh Astragalus root was 708. 9 kg /666. 7 m2,and was31. 1% increased compared with the control variety; special / first class rate was 21. 5%,30. 6%,in which were 4. 8,5. 3 percentage points higher than that of the control variety, respectively; root rot disease incidence and disease index were 25. 7%,13. 5%,in which were 2. 75,2. 17 percentage points reduced compared with control variety; intrinsic quality were as follows, the total ash was 4. 5%,the extract was 41. 0%,the content of calycosin was 0. 10%,and the content of astragaloside was 0. 076%,respectively,which superior than the 2010 edition of the standard of the Pharmacopoeia of the People’ s Republic of China.

Conclusion: A new Astragalus variety of Longqi 4 is high-yield, good-quality, disease-resistant, anti-inverse and its intrinsic quality in lines with the standard of the Pharmacopoeia of the People’s Republic of China. Longqi 4 is suitable for application at an altitude of 1 900 ~ 2 400 m, the annual average temperature of 5 ~ 8 ℃,semi-arid and cold damp ecological area of annual precipitation of 450 ~ 550 mm.

本刊更多论文

黄芪新品种龙芪4号的栽培及标准化技术研究

目的:选育一种高产、优质、抗病、抗倒转、内在品质符合《中华人民共和国药典》标准的黄芪新品种，并研究其标准栽培技术。方法:采用单株选育法，2003年筛选出优秀单株15株→2004年种子期试验→2005 - 2007年品系鉴定试验→2008 - 2010年药期HQZX04-04-01新品系比对试验→2011 - 2014年HQZX04-04-01区域试验及生产示范试验→2015年4月龙七四号通过甘肃省作物品种审定委员会命名。结果:选育了黄芪新品种龙芪4号(原牌号HQZX04-04-01)。在不同生态区进行3 n次试验，平均鲜黄芪产量为708根。9公斤/666。7平方米，是31。比对照品种增加1%;特别/头等费率是21。5%, 30。6%，其中4人。8、5。分别比对照品种高3个百分点;根腐病发病率和病害指数均为25。7%, 13岁。5%，其中2人。75年,2。与对照品种相比降低了17个百分点;内在质量如下，总灰分为4。5%，提取物为41。0%，毛蕊异黄酮含量为0。10%，黄芪甲苷含量为0。分别为076%，优于2010年版《中华人民共和国药典》标准。结论:龙芪4号黄芪新品种高产、优质、抗病、抗逆，其内在品质符合《中华人民共和国药典》标准。龙旗4号适宜应用于海拔1 900 ~ 2 400 m，年平均气温5 ~ 8℃，年降水量450 ~ 550 mm的半干旱寒湿生态区。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

中药材

自引率

0.00%

发文量

11364

期刊介绍： "Chinese Materia Medica" magazine was founded in 1978. It is a national-level academic journal of Chinese medicine science and technology approved by the State Science and Technology Commission and the Press and Publication Administration for public distribution at home and abroad. It is sponsored by the Chinese Materia Medica Information Center of the State Food and Drug Administration and is publicly distributed at home and abroad. It mainly reports on new technologies, new methods and new achievements in the production, scientific research and business management of Chinese medicine, and serves to promote the production and scientific and technological development of Chinese medicine, improve the output and quality of Chinese medicine, improve business management, and prosper the Chinese medicine industry.